In my last letter to Shareholders, I discussed the importance of the year 2010 in shaping the field of cancer immunotherapies. In 2011, Advaxis continued to develop constructs using our proprietary platform, create scientific collaborations with recognized research centers, and move our therapies towards the clinic. As I look forward to 2012, I appreciate the progress we have made and believe that we are opening the door to a truly innovative way to treat cancer.
Tom Moore
Chairman & Chief Executive Officer
Advaxis, Inc.